Request Trial
1 July 2014

Bingham boosts life sciences practice

Patent counselling specialist Mark Hayman has joined Bingham McCutchen LLP’s Boston office as a partner.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
European court backs AstraZeneca unit in blood cancer combo dispute
28 May 2026   A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.
Asia
Takeda’s China IP head: What pharma is still getting wrong
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Careers
Boehringer Ingelheim adds ex-Teva executive to patent team
27 May 2026   A senior pharmaceutical lawyer, with experience across private practice and Big Pharma, joins the company after a decade-long tenure at Teva.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

European court backs AstraZeneca unit in blood cancer combo dispute
Takeda’s China IP head: What pharma is still getting wrong
Boehringer Ingelheim adds ex-Teva executive to patent team
AI, anxiety, and antibodies: The issues dominating life sciences
UPC judge: ‘Expectations of you as a woman are the challenge’
How should in-house teams adopt AI? ‘Carefully’, says secrets expert
Lupin scores another win in kidney drug dispute
Battle over inhaler shape ends badly for Boehringer